eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study
Portfolio Pulse from Vandana Singh
eFFECTOR Therapeutics Inc (NASDAQ:EFTR) released interim data from a Phase 1/2 study of zotatifin in ER+ metastatic breast cancer patients. The ZFA triplet cohort showed a median progression-free survival of 7.4 months with a 26% partial response rate. Zotatifin was well tolerated with most adverse events being Grade 1 or 2. No serious adverse events were observed in the new ZF dose escalation cohorts, and enrollment continues at higher doses. Additional data is expected in the first half of 2024. EFTR shares rose 2.94% to $0.59.
December 08, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
eFFECTOR Therapeutics Inc reported positive interim data from a study of zotatifin in breast cancer, with shares rising 2.94% to $0.59.
The positive interim data from the clinical study indicates potential for zotatifin as a treatment for ER+ metastatic breast cancer, which is likely to be viewed favorably by investors. The increase in share price reflects the market's initial positive reaction to the news. The continued enrollment at higher doses and the anticipation of additional data in the first half of 2024 could maintain investor interest and potentially lead to further stock price increases in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100